AACR 2013

Certain Bacteria Linked to Elevated Risk of Pancreatic Cancer

Certain Bacteria Linked to Elevated Risk of Pancreatic Cancer

By

The presence of 2 species of bacteria was associated with an elevated risk for developing pancreatic cancer.

High Tumor HER2 Predicts Greatest Benefit from T-DM1 Breast Cancer Treatment

By

Women with metastatic, HER2-positive breast cancer with tumors that express high levels of HER2 derived the greatest survival benefit from treatment with trastuzumab emtansine (T-DM1), according to research presented at AACR 2013.

Autologous-Collected T-Cell Immunotherapy Shows Promising Antileukemia Activity in Children

By

Using autologous T-cell immunotherapy to attack leukemia cells showed early promise in two children diagnosed with relapsing acute lymphoblastic leukemia after bone marrow transplant, according to research presented at AACR 2013.

Survivors of Melanoma Need to Remain Vigilant About Sun Exposure, Tanning Beds

By

Melanoma survivors often do not take protective measures to prevent skin cancer recurrence, according to research presented at AACR 2013.

Prevalence of Benign Findings after Lung Surgery Varies Geographically

By

The number of benign findings for suspected lung cancers varies by state, suggesting a national lung cancer screening program would vary geographically, according to research presented at AACR 2013.

PLK1-Targeting RNAi Drug is Well-Tolerated and Demonstrates Potential Therapeutic Benefit

By

The RNA interference (RNAi) drug TKM-080301 can be safely administered to patients with advanced solid tumors or lymphoma, and some patients show therapeutic benefit, according to research presented at AACR 2013.

Novel AKT Pathway Inhibitor ARQ 092 Safe in Phase 1 Trial

By

The novel oral selective AKT pathway inhibitor ARQ 092 exhibits a manageable safety profile among patients with advanced solid tumors, according to research presented at AACR 2013.

In KRAS-Mutant Non-Small Cell Lung Cancer, Biomarkers May Predict Sensitivity to Combined MEK/PI3K Inhibition

By

Newly identified biomarkers may predict sensitivity to combined MEK and PI3K inhibition in patients with KRAS-mutant NSCLC, according to research presented at AACR 2013.

Higher Incidence of Childhood ALL, Retinoblastoma, Germ Cells Tumors Linked to Air Pollution

By

Increased exposure to traffic-related air pollution during pregnancy and early life was associated with a higher incidence of acute lymphoblastic leukemia, retinoblastoma, and germ cell tumors, according to research presented at AACR 2013.

Single-Agent Ibrutinib Highly Effective for Patients with Relapsed/Refractory CLL

By

Ibrutinib is well tolerated and highly effective in patients with chronic lymphocytic leukemia, according to research presented at AACR 2013.

Noteworthy Abstracts from American Association for Cancer Research (AACR) 2013

Noteworthy Abstracts from American Association for Cancer Research (AACR) 2013

By

Dr. Barbara Burtness' recommended abstracts from the American Association for Cancer Research 2013 Annual Meeting.

Combination Immunotherapy Approach Offers Clinical Benefit in Recurrent Ovarian Cancer

By

Combining dendritic cell-based autologous whole tumor antigen vaccination with adoptive lymphocyte transfer using tumor antigen-specific T cells shows promise in treating women with recurrent ovarian cancer, according to research presented at AACR 2013.

Intermittent Dosing Might Prevent Vemurafenib Resistance in Melanoma

By

Intermittent dosing might delay or prevent the development of vemurafenib resistance and drug-dependent tumor growth in patients with melanoma, according to research presented at AACR 2013.

African American Women Have Higher Mortality from Breast Cancer Not Explained by Subtype

By

African American women have worse survival and less treatable breast cancer, but higher mortality observed cannot be attributed entirely to differential diagnosis by subtype, according to research presented at AACR 2013.

Early Safety, Efficacy Demonstrated for Investigational PI3 Kinase Inhibitor GDC-0032 against Some Breast Cancers

By

The investigational oral PI3 kinase inhibitor GDC-0032 exhibits a favorable safety profile and early signs of promising activity against PI3 kinase alpha-mutation hormone receptor-positive breast tumors, according to research presented at the American Association for Cancer Research Annual Meeting 2013.

Novel ERK Inhibitor Shows Preclinical Promise Against BRAF, MEK-associated Drug Resistance

By

SCH772984 shows promise against tumor growth driven by BRAF and RAS mutations and might prove useful against tumor resistance to BRAF and MEK inhibitors, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2013.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs